RxDoctor Payments Data

Francis Mc Cormick, MD

Gastroenterology · St Joseph, MONPI 1427061654

Payments from drug & device makers

$4,653in general payments, 2019–2025

Across 188 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apollo Endosurgery US Inc$1K
  • AbbVie$1K
  • Johnson & Johnson$621
  • Takeda Pharmaceuticals U.S.A., Inc.$458
  • Pfizer$297
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$187
  • plus $949 from 17 others

What the payments were for

  • Travel & lodging$1,10024%
  • Food & beverage$3,51576%
  • Education$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,653 in reported general payments places this provider in the 65th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$170,352
Medicare patients
692
Services billed
1,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid18$214,936
LinzessLinaclotide19$14,687
Budesonide DrBudesonide22$8,458
Pantoprazole Sodium567$8,089
Mesalamine16$6,918
Balsalazide Disodium12$3,236
Sucralfate86$2,226
Omeprazole140$1,974
Esomeprazole Magnesium46$1,007
Lubiprostone12$707
Lansoprazole20$609
Famotidine48$596
Fluconazole24$354
Metoclopramide Hcl41$295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$92$214,93618 claims
AbbVieLinzess$1,031$14,68719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in St Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →